Loading...
OTCM
INFIQ
Market cap0kUSD
Jun 02, Last price  
0.00USD
Name

Infinity Pharmaceuticals Inc

Chart & Performance

D1W1MN
OTCM:INFIQ chart
P/E
—
P/S
0.00
EPS
—
Div Yield, %
—
Shrs. gr., 5y
12.04%
Rev. gr., 5y
-15.45%
Revenues
3m
+39.56%
49,826,59251,564,04834,836,97718,494,55824,536,35083,440,66649,538,71471,330,98792,773,16247,114,0000164,995,000109,066,00018,723,0006,000,00022,146,0003,049,0001,719,0001,858,0002,593,000
Net income
-43m
L-4.81%
1,058,9133,902,772-14,164,737-28,447,973-16,897,88723,654,357-32,505,265-48,983,659-40,042,101-53,964,000-126,780,000-17,416,000-128,376,000-30,101,000-41,830,000-11,253,000-47,057,000-42,937,000-45,442,000-43,256,000
CFO
-42m
L+4.46%
8,127,3864,749,9746,056,5759,655,70712,082,295-10,422,417-4,756,922-26,585,050-33,108,955-80,135,000-113,907,000117,715,000-83,653,000-154,356,000-36,711,000-4,714,000-41,530,000-35,739,000-40,618,000-42,431,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Infinity Pharmaceuticals, Inc., established in 1995 and based in Cambridge, Massachusetts, operates as a biopharmaceutical firm dedicated to creating innovative therapies for individuals battling cancer. A central component of its pipeline is IPI-549, an experimental immuno-oncology drug taken orally. This candidate, currently in clinical development, functions by blocking the phosphoinositide-3-kinase-gamma enzyme. IPI-549 is undergoing Phase 2 trials for metastatic triple negative breast cancer and urothelial cancer, and Phase 1/1b trials for various solid tumors. The company maintains several strategic partnerships: with Intellikine, Inc. for the discovery, development, and commercialization of PI3K delta and/or gamma isoform-targeting pharmaceuticals; with Verastem, Inc. for the research, development, commercialization, and production of duvelisib and related compounds; and with PellePharm, Inc. to advance and commercialize its hedgehog inhibitor program, IPI-926, which is also a clinical-stage investigational drug. Furthermore, Infinity Pharmaceuticals holds collaborative agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company.
URL
https://www.infi.com/
IPO date
Jul 27, 2000
Employees
30
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT